Phaxiam Therapeutics SA (PHXM)

Overview

PHAXIAM Therapeutics S.A. is a biopharmaceutical company dedicated to developing innovative treatments for resistant bacterial infections primarily in France and the United States. With a strong focus on addressing the challenges posed by antibiotic resistance, the company is advancing its pipeline to target various cancers and severe bacterial infections. One of its lead product candidates, eryaspase, is currently undergoing Phase 3 clinical development for the treatment of second-line pancreatic cancer and is in Phase 2 trials for treating triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. In addition, the company is working on a promising portfolio of phages aimed at combating resistant and dangerous bacteria, which are responsible for a significant proportion of hospital-acquired infections. Established in 2004 and formerly known as ERYTECH Pharma S.A., PHAXIAM Therapeutics S.A. rebranded in June 2023 and is headquartered in Lyon, France.

Products and Services

• Eryaspase

  Eryaspase is a biopharmaceutical product that harnesses the technology of encapsulating L-asparaginase in red blood cells. It is in Phase 3 clinical development for treating second-line pancreatic cancer and is also being evaluated in Phase 2 clinical trials for triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. This innovative approach aims to improve drug efficacy and reduce side effects compared to traditional treatments.

• Phage Therapy Portfolio

  PHAXIAM Therapeutics is developing a comprehensive portfolio of phages aimed at targeting and eliminating resistant bacteria, such as staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. These phages are vital in addressing the issue of antibiotic resistance, especially in hospital settings, where they can provide alternative treatment options for infections that do not respond to conventional antibiotics.